Molecular imaging to enlighten cancer immunotherapies and underlying involved processesvan der Veen, E. L., Bensch, F., Glaudemans, A. W. J. M., Lub-de Hooge, M. N. & de Vries, E. G. E., Nov-2018, In : CANCER TREATMENT REVIEWS. 70, p. 232-244 13 p.
Research output: Contribution to journal › Review article › Academic › peer-review
C Cancer immunotherapy has led to impressive antitumor effects. However, not all patients respond to immunotherapy, serious toxicity can occur and combination therapy may be warranted. Strategies for rational early treatment choices are urgently required. In the absence of ideal accompanying biomarkers it remains challenging to capture the dynamic, heterogeneous and complex tumor behavior. Tumor immune response involves next to tumor cells, numerous other cells and molecules in the tumor microenvironment. We review research to identify potential novel imaging biomarkers by non-invasive whole body molecular imaging with positron emission tomography and single-photon emission computed tomography for cancer immunotherapy. Firstly, imaging with radiolabeled immune checkpoint targeting molecules. Secondly, imaging of immune cells with ex vivo or in vivo radiolabeled tracers and thirdly, imaging extracellular matrix components, including adhesion molecules, growth factors and cytokines. These molecular imaging strategies used alone, in combination or serially could potentially contribute to patient selection upfront or early during immunotherapy.
|Number of pages||13|
|Journal||CANCER TREATMENT REVIEWS|
|Publication status||Published - Nov-2018|
- Molecular imaging, Immunotherapy, Biomarkers, Immune checkpoints, Immune cells, TUMOR-ASSOCIATED MACROPHAGES, PD-1 CHECKPOINT EXPRESSION, IMMUNO-PET, IN-VIVO, SUPPRESSOR-CELLS, MONOCLONAL-ANTIBODY, INDOLEAMINE 2,3-DIOXYGENASE, INFILTRATING LYMPHOCYTES, RESPONSE CRITERIA, T-LYMPHOCYTES